Recent Updates
Recently added Catalysts
SNDX Positive Sentiment

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Monday, January 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Syndax Pharmaceuticals announced that CEO Michael A. Metzger will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be available via live webcast and later as a replay. The company is known for its innovative cancer therapies, including FDA-approved treatments.
Price reaction · baseline $21.3 (2026-01-02 close) · hit pre-market · 1 other SNDX headline(s) in the window, move may be shared
day 0 close · peak
-5.1%
day 1
-4.5%
day 3
+0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Syndax Pharmaceuticals is advancing innovative cancer therapies.
  • CEO Michael A. Metzger will present at a major healthcare conference.
  • The company has FDA-approved therapies in its pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+133%
120-day peak, hindsight
Typical move
5.3%
average across 8 past catalysts
Cash runway
~54 mo
Low dilution risk
Lead asset
entinostat
Phase 1 · Epithelial Ovarian Cancer

Full Press Release Details

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 3:00 p.m. PT/ 6:00 p.m. ET.
A live webcast of the presentation will be available in the Investor section of the Company's website atwww.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj®(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.com/or follow the Company onXandLinkedIn.

Syndax ContactsSharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827

SNDX-G

Frequently Asked Questions

When will Syndax present at the J.P. Morgan Conference?

Syndax will present on January 12, 2026, at 3:00 p.m. PT.

Where can I watch the Syndax presentation?

The presentation will be available via live webcast on Syndax's website.

What are Syndax's notable therapies?

Syndax's pipeline includes FDA-approved Revuforj® and Niktimvo™.

Who is presenting for Syndax at the conference?

CEO Michael A. Metzger will present at the conference.

ShareAdd on Google
Tags: SNDX Viatris Investor Conferences Healthcare Syndax Pharmaceuticals J.P. Morgan Healthcare Conference cancer therapies FDA-approved
Last updated: Jan 5, 2026

Biotech snapshot

Cash runway
$548M liquidity · $10M/mo burn
~54 mo
Low dilution risk
Lead asset
entinostatPhase 1
Epithelial Ovarian Cancer →

Catalyst track record

+133%
best trade around SNDX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for SNDX.

See every catalyst's timing & PoA →